Proto-Oncogene Proteins B-raf
"Proto-Oncogene Proteins B-raf" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A raf kinase subclass found at high levels in neuronal tissue. The B-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2.
| Descriptor ID |
D048493
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.559.842.374 D12.644.360.400.842.374 D12.776.476.400.842.437 D12.776.624.664.700.204.200
|
| Concept/Terms |
Proto-Oncogene Proteins B-raf- Proto-Oncogene Proteins B-raf
- B-raf, Proto-Oncogene Proteins
- Proteins B-raf, Proto-Oncogene
- Proto Oncogene Proteins B raf
- BRAF Kinases
- B-raf Kinases
- B raf Kinases
- Proto-Oncogene Protein B-raf
- B-raf, Proto-Oncogene Protein
- Protein B-raf, Proto-Oncogene
- Proto Oncogene Protein B raf
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins B-raf".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins B-raf".
This graph shows the total number of publications written about "Proto-Oncogene Proteins B-raf" by people in this website by year, and whether "Proto-Oncogene Proteins B-raf" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 0 | 3 |
| 2013 | 0 | 4 | 4 |
| 2014 | 10 | 1 | 11 |
| 2015 | 5 | 4 | 9 |
| 2016 | 7 | 3 | 10 |
| 2017 | 8 | 2 | 10 |
| 2018 | 4 | 1 | 5 |
| 2019 | 5 | 3 | 8 |
| 2020 | 4 | 5 | 9 |
| 2021 | 2 | 6 | 8 |
| 2022 | 2 | 6 | 8 |
| 2023 | 1 | 5 | 6 |
| 2024 | 3 | 4 | 7 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins B-raf" by people in Profiles.
-
Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma. J Immunother Cancer. 2025 Feb 12; 13(2).
-
Mutational and co-mutational landscape of early onset colorectal cancer. Biomarkers. 2025 Feb; 30(1):64-76.
-
Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol. 2024 Dec 01; 10(12):1672-1680.
-
Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer. Clin Cancer Res. 2024 Nov 15; 30(22):5166-5179.
-
Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma. Cancer Med. 2024 Oct; 13(19):e70313.
-
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase?3 BEACON CRC trial. Nat Med. 2024 Nov; 30(11):3261-3271.
-
Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol. 2024 Sep 01; 10(9):1264-1271.
-
Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma. J Clin Invest. 2024 Aug 13; 134(19).
-
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G. Oncologist. 2024 Aug 05; 29(8):723-e1093.
-
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies. J Immunother Cancer. 2024 Jul 29; 12(7).